Abstract
Background and aim
Gastroesophageal reflux disease (GERD) and functional dyspepsia (FD) are frequently overlapped. However, no treatment strategies have been established yet for such patients. This study compared the effects of proton pump inhibitor (PPI) treatment in patients with GERD-associated FD among three groups with varying severity levels of GERD symptoms.
Methods
The patients with GERD and FD symptoms received PPI treatment for 4 weeks after endoscopy, and the severity of the symptoms and responses to treatment were evaluated at before and after 4 weeks of treatment using the Gastroesophageal Reflux and Dyspepsia Therapeutic Efficacy and Satisfaction Test (GERD-TEST). The patients were divided into three groups in accordance with the severity of the GERD symptoms as assessed by the GERD symptom subscale (SS) scores of pre-treatment.
Results
Data from 233 cases of 40 mild, 151 moderate and 42 severe symptoms were analyzed. Analysis of the pre-treatment scores for each symptom revealed that a higher GERD-SS score was significantly associated with higher scores on any kind of FD score. Four weeks of PPI treatment significantly and markedly alleviated any of GERD/FD symptoms. Most importantly, change in the score for each symptom after 4 weeks of treatment relative to the pre-treatment score was significantly greater in the groups with more severe GERD-SS.
Conclusion
FD symptoms associated with more severe GERD symptoms are supposed to be acid-related dyspepsia, and PPI monotherapy is recommended as the treatment of first choice in such patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Change history
11 March 2019
In the original publication of this article, Tables 2, 3, 4, 5 and 6 were published incorrectly. The correct tables are given below.
References
Durk R, Margot A, Herwaarden V, et al. Concomitant functional dyspepsia and irritable bowel syndrome decrease health-related quality of life in gastroesophageal reflux disease. Scand J Gastroenterol. 2007;42:951–6.
Fujiwara Y, Arakawa T. Overlap in patients with dyspepsia/functional dyspepsia. J Neurogastroenterol Motil. 2014;20:447–57.
Nakada K, Matsuhashi N, Iwakiri K, et al. Development and validation of a simple and multifaceted instrument, GERD-TEST, for the clinical evaluation of gastroesophageal reflux and dyspeptic symptoms. World J Gastroenterol. 2017;23:5216–28.
Hongo M. Epidemiology of FGID symptoms in Japanese general population with reference to life style. J Gastroenterol Hepatol. 2011;26:19–22.
Miwa H, Kusano M, Arisawa T, et al. Japanese Society of Gastroenterology. Evidence-based clinical practice guidelines for functional dyspepsia. J Gastroenterol. 2015;50:125–39.
Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med. 1999;159:649–57.
van Pinxteren B, Sigterman KE, Bonis P, et al. Short-term treatment with proton pump inhibitors: H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2010;10:CD002095.
Miwa H, Nakajima K, Yamaguchi K, et al. Generation of dyspeptic symptoms by direct acid infusion into the stomach of healthy Japanese subjects. Aliment Pharmacol Ther. 2007;26:257–64.
Oshima T, Okugawa T, Tomita T, et al. Generation of dyspeptic symptoms by direct acid and water infusion into the stomachs of functional dyspepsia patients and healthy subjects. Aliment Pharmacol Ther. 2012;35:175–82.
Ishii M, Kusunoki H, Manabe N, et al. Evaluation of duodenal hypersensitivity induced by duodenal acidification using transnasal endoscopy. Aliment Pharmacol Ther. 2012;35:175–82.
Matsuhashi N, Kudo M, Yoshida N, et al. Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study. J Gastroenterol. 2015;50:1173–83.
Kaji M, Fujiwara Y, Shiba M, et al. Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life. J Gastroenterol Hepatol. 2010;25:1151–6.
Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016;51:751–67.
Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II–IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798–810.
Quartero AO, de Wit NJ, Lodder AC, et al. Disturbed solid-phase gastric emptying in functional dyspepsia: a meta-analysis. Dig Dis Sci. 1998;43:2028–33.
Kusunoki H, Haruma K, Manabe N, et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil. 2012;24:540–5.
Lemann M, Dederding JP, Flourie B, et al. Abdominal perception of visceral pain in response to gastric distension in chronic idiopathic dyspepsia. The irritable stomach syndrome. Dig Dis Sci. 1991;36:1249–54.
Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical symptoms, anxiety, and depression: a metaanalytic review. Phychosom Med. 2003;65:528–33.
Jones RH, Baxter G. Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice. Aliment Pharmacol Ther. 1997;11:541–6.
Kusano M, Shimoyama Y, Kawamura O, et al. Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal Reflux disease patients. Dig Dis Sci. 2007;52:1673–7.
Bratten J, Jones MP. Prolonged recording of duodenal acid exposure in patients with functional dyspepsia and controls using a radiotelemetry pH monitoring system. J Clin Gastroenterol. 2009;43:527–33.
Lee KJ, Kim JH, Cao SW. Dyspeptic symptoms associated with hypersensitivity to gastric distension induced by duodenal acidification. J Gastroenterol Hepatol. 2016;21:515–20.
Lee KJ, Vos R, Janssens VJ, et al. Influence of duodenal acidification on the sensorimotor function of the proximal stomach in humans. Am J Physiol Gastrointest Liver Physiol. 2004;286:278–84.
Acknowledgments
This study was conducted by the GERD Society and registered to UMIN-CTR #000006614. Financial support for this clinical study was provided by GERD Society (Osaka, Japan). This study was completed by 29 institutions in Japan. The authors thank all physicians who participated in this study and the patients whose cooperation made this study possible. The contributor of each institution is listed below.
Nobuyuki Matsuhashi, NTT Medical Center Tokyo; Mineo Kudo, Sapporo Hokuyu Hospital; Norimasa Yoshida and Takahiro Suzuki, Japanese Red Cross Kyoto Daiichi Hospital; Kazunari Murakami and Seiji Shiota, Oita University Faculty of Medicine; Mototsugu Kato and Katsuhiro Mabe, Hokkaido University Hospital; Tsuyoshi Sanuki and Junko Hori, Kita Harima Medical Center; Noriaki Manabe and Ken Haruma, Kawasaki Medical School; Yuji Naito and Osamu Handa, Kyoto Prefectural University of Medicine; Syuuji Inoue, National Hospital Organization Kochi Hospital; Hirokazu Oyamada and Yutaka Isozaki, Matsushita Memorial Hospital; Shuichi Muto, Tomakomai City Hospital; Kenji Furuta and Shunji Ohara, Shimane University Faculty of Medicine; Tadayuki Oshima and Hiroto Miwa, Hyogo College of Medicine; Yasuhiro Fujiwara and Yukie Kohata, Osaka City University Graduate School of Medicine; Kazuhiro Maeda and Yuji Sakai, Tenjin Clinic, Medical Corporation Shinai; Yugo Iwaya and Sadahisa Okuhara, Shinshu University School of Medicine; Takashi Abe and Yongmin Kim, Takarazuka Municipal Hospital; Hideki Mizuno, Toyama City Hospital;
Kimio Isshi, Isshi Gastro-Intestinal Clinic; Hiroshi Seno and Tsutomu Chiba, Kyoto University Hospital; Fukunori Kinjo and Manabu Nakamoto, University Hospital, University of the Ryukyus; Toshiro Sugiyama and Haruka Fujinami, University of Toyama; Keiko Utsumi, Aichi Medical University Medical Clinic; Hiroyuki Kuwano and Tatsuya Miyazaki, Gunma University Hospital; Noriko Watanabe, National Hospital Organization Mie Chuo Medical Center; Fumihiko Kinekawa and Kita Yuko, Sanuki Municipal Hospital; Tomonori Imaoka and Hirohumi Fujishiro, Shimane Prefectural Central Hospital; Takatsugu Yamamoto and Yasushi Kuyama, Teikyo University School of Medicine; Yasuaki Nakajima and Kenro Kawada, Tokyo Medical and Dental University.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Kazuhide Higuchi received a research grants and lecture fees from Takeda Pharmaceutical Company Limited (Takeda), Daiichi Sankyo Company Limited (Daiichi Sankyo), Otsuka Pharmaceutical Company Limited (Otsuka), EA Pharma Company Limited (EA Pharma), Astellas Pharmaceutical Company Limited (Astellas) and Astra Zeneca Company Limited (Astra Zeneca). Takeshi Kamiya received research grants from AstraZeneca, Astellas, Daiichi Sankyo, Mylan EPD. Noriaki Manabe received research grants and lecture fees from Astellas, Mylan EPD. Ken Haruma received research grants and lecture fees from Astellas, AstraZeneca, Daiichi Sankyo, Otsuka and Takeda. The other authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Isshi, K., Matsuhashi, N., Joh, T. et al. Proton pump inhibitor monotherapy is effective to attenuate dyspepsia symptoms associated with gastroesophageal reflux disease: a multicenter prospective observational study. J Gastroenterol 54, 492–500 (2019). https://doi.org/10.1007/s00535-019-01546-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00535-019-01546-0